KERX Keryx Biopharmaceuticals, Inc.

5.90
+0  (1%)
Previous Close 5.83
Open 5.87
Price To book 0.00
Market Cap 635.24M
Shares 107,667,000
Volume 1,517,824
Short Ratio 14.17
Av. Daily Volume 1,341,500

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved Sept 5, 2014.
Auryxia
Hyperphosphatemia
(sNDA) PDUFA date November 6, 2017.
Auryxia
Iron deficiency anemia in non-dialysis dependent CKD patients

Latest News

  1. Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2017 Financial Results on Thursday, May 4, 2017
  2. Lawsuit for Investors in NASDAQ: KERX Shares Against Keryx Biopharmaceuticals Announced by Shareholders Foundation
  3. ETFs with exposure to Keryx Biopharmaceuticals, Inc. : April 7, 2017
  4. Here's Why Keryx Biopharmaceuticals Jumped 27.3% in March
  5. Why Is Keryx (KERX) Up 27.4% Since the Last Earnings Report?
  6. Keryx's Auryxia Added to Largest Medicare Part D Plan
  7. Omeros and Keryx are Potential Beneficiaries of New Administration Deregulation
  8. Keryx Announces the Largest Medicare Part D Plan Sponsor Added Auryxia® to its Medicare Part D Plan Formularies
  9. Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat
  10. Blog Coverage Keryx Biopharma Announced FDA Review Approval for Auryxia(R) Tablets
  11. 3 Top Stocks Under $5
  12. Keryx Biopharmaceuticals Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Auryxia® (ferric citrate) Tablets
  13. Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  14. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Keryx Biopharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  15. Keryx (KERX) Q4 Loss Wider than Expected, Revenues Beat
  16. Edited Transcript of KERX earnings conference call or presentation 1-Mar-17 1:00pm GMT
  17. Keryx (KERX) Posts Wider-than-Expected Loss in Q4
  18. Keryx Biopharma reports 4Q loss
  19. Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results
  20. Should You Sell Keryx Biopharmaceuticals (KERX) Before Earnings?